ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet201428-12ometendo-6716Research ArticleСтатьиArticlesРоль липотоксичности в патогенезе сахарного диабета 2 типа и ожиренииThe role of the lipotoxicity in the pathogenesis of type 2 diabetes mellitus and obesityAbdulkadirovaF R

Кафедра эндокринологии и диабетологии; ГБОУ ДПО РМАПО Минздрава России

endo284@mail.ruAmetovA S

Кафедра эндокринологии и диабетологии; ГБОУ ДПО РМАПО Минздрава России

alexander.ametov@gmail.comDoskinaE V

Кафедра эндокринологии и диабетологии; ГБОУ ДПО РМАПО Минздрава России

elena-doskina@rambler.ruPokrovskayaR A

Кафедра эндокринологии и диабетологии; ГБОУ ДПО РМАПО Минздрава России

sherrkat86@mail.ru201415062014112№2 (2014)812Copyright © Abdulkadirova F.R., Ametov A.S., Doskina E.V., Pokrovskaya R.A., 20142014Abdulkadirova F.R., Ametov A.S., Doskina E.V., Pokrovskaya R.A.Abdulkadirova F.R., Ametov A.S., Doskina E.V., Pokrovskaya R.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/6716

Ожирение является главным фактором риска развития сахарного диабета 2 типа (СД2), сердечно-сосудистых заболеваний и ассоциированных с ними коморбидных состояний. Традиционно считалось, что инсулинорезистентность определяется метаболизмом глюкозы. Однако в последние годы все больше и больше внимания уделяется обмену жирных кислот в организме, повышение уровня которых играет значительную роль в патофизиологических механизмах, связанных с инсулинорезистентностью.

Obesity is a major risk factor for diabetes mellitus type 2, cardiovascular diseases and associated comorbid conditions. It is traditionally considered that insulin resistance is dependent on glucose metabolism. However, in recent years more and more attention is devoted to the fatty acids metabolism, the increase in concentrations of which plays a significant role in the pathophysiological mechanisms associated with insulin resistance.

ожирениеинсулинорезистентностьжирные кислотыobesityinsulin resistancefatty acidsReferencesDiabetes Atlas, 2011.Diabetes Atlas, 2011.Аметов А.С. Факторы риска сахарного диабета. Роль ожирения. Русский медицинский журнал. 2003;11(27):1477-1480.Аметов А.С. Факторы риска сахарного диабета. Роль ожирения. Русский медицинский журнал. 2003;11(27):1477-1480.Hossain P., Kawar B. et al. Obesity and Diabetes in the Developing World - A Growing Challenge. NEnglJMed. 2007;356:213-215.Hossain P., Kawar B. et al. Obesity and Diabetes in the Developing World - A Growing Challenge. NEnglJMed. 2007;356:213-215.Eckel RH, Kahn SE et al. Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized? Diabetes Care. 2011;34:1424-1430.Eckel RH, Kahn SE et al. Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized? Diabetes Care. 2011;34:1424-1430.FujiokaK, Seaton TB et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2000;2:175-187.FujiokaK, Seaton TB et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2000;2:175-187.Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab. 2002;28:437-445.Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab. 2002;28:437-445.Kusminski CM, Shetty S, Orci L, Unger RH, Scherer PE. Diabetes and apoptosis: lipotoxicity. Apoptosis. 2009;14:1484-1495.Kusminski CM, Shetty S, Orci L, Unger RH, Scherer PE. Diabetes and apoptosis: lipotoxicity. Apoptosis. 2009;14:1484-1495.Randle PJ, Garland PB, Hales CN et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.Randle PJ, Garland PB, Hales CN et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.Unger R.H. Lipotoxic diseases. Ann. Rev. Med. 2002;53:319-336.Unger R.H. Lipotoxic diseases. Ann. Rev. Med. 2002;53:319-336.Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.Boden G. Obesity, Insulin Resistance and Free Fatty Acids. Curr Opin Endocrinol Diabetes Obes. 2011;18:139-143.Boden G. Obesity, Insulin Resistance and Free Fatty Acids. Curr Opin Endocrinol Diabetes Obes. 2011;18:139-143.Ebbert JO, Jensen MD. Fat Depots, Free Fatty Acids, and Dyslipidemia. Nutrients. 2013;5:498-508.Ebbert JO, Jensen MD. Fat Depots, Free Fatty Acids, and Dyslipidemia. Nutrients. 2013;5:498-508.Nielsen S, Guo Z, Albu JB, Klein S, O’Brien PC, Jensen MD. Energy expenditure, sex, and endogenous fuel availability in humans. J Clin Invest. 2003;111:981-988.Nielsen S, Guo Z, Albu JB, Klein S, O’Brien PC, Jensen MD. Energy expenditure, sex, and endogenous fuel availability in humans. J Clin Invest. 2003;111:981-988.Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74:761-811.Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev. 1994;74:761-811.Horowitz JF, Coppack SW, Paramore D, Cryer PE, Zhao G, Klein S. Effect of short-term fasting on lipid kinetics in lean and obese women. Am J Physiol. 1999;276:E278-E284.Horowitz JF, Coppack SW, Paramore D, Cryer PE, Zhao G, Klein S. Effect of short-term fasting on lipid kinetics in lean and obese women. Am J Physiol. 1999;276:E278-E284.Campos G, Fernández V, Fernández E et al. Association of free fatty acids with the insulin-resistant state but not with central obesity in individuals from Venezuela. Invest Clin. 2010;51:115-126.Campos G, Fernández V, Fernández E et al. Association of free fatty acids with the insulin-resistant state but not with central obesity in individuals from Venezuela. Invest Clin. 2010;51:115-126.Guo Z, Hensrud DD, Johnson CM, Jensen MD Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes. 1999;48:1586-1592.Guo Z, Hensrud DD, Johnson CM, Jensen MD Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes. 1999;48:1586-1592.Roust LR, Jensen MD Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes. 1993;42:1567-1573.Roust LR, Jensen MD Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes. 1993;42:1567-1573.Reaven GM, Hollenbeck C, Jeng CY et al. Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM. Diabetes. 1988;37:1020-1024.Reaven GM, Hollenbeck C, Jeng CY et al. Measurement of Plasma Glucose, Free Fatty Acid, Lactate, and Insulin for 24 h in Patients With NIDDM. Diabetes. 1988;37:1020-1024.Pankow JS, Duncan BB, Schmidt MI Fasting Plasma Free Fatty Acids and Risk of Type 2 Diabetes. Diabetes Care. 2004;27:77-82.Pankow JS, Duncan BB, Schmidt MI Fasting Plasma Free Fatty Acids and Risk of Type 2 Diabetes. Diabetes Care. 2004;27:77-82.Kashyap S, Belfort R, Gastaldelli A et al. A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. Diabetes. 2003;52:2461-2474.Kashyap S, Belfort R, Gastaldelli A et al. A Sustained Increase in Plasma Free Fatty Acids Impairs Insulin Secretion in Nondiabetic Subjects Genetically Predisposed to Develop Type 2 Diabetes. Diabetes. 2003;52:2461-2474.Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and p-cell dysfunction. Eur J Clin Invest. 2002;32 Suppl 3:14-23.Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and p-cell dysfunction. Eur J Clin Invest. 2002;32 Suppl 3:14-23.Bruneau G, Vaisse C, Caraty A, Monget P: Leptin. A key for reproduction. Med Sci. 1999;15:191-196.Bruneau G, Vaisse C, Caraty A, Monget P: Leptin. A key for reproduction. Med Sci. 1999;15:191-196.Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes. Pwe Natl Acad Sci USA.1998;95:2498-2502.Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes. Pwe Natl Acad Sci USA.1998;95:2498-2502.Miller MR, Pereira RI, Langefeld CD et al. Levels of Free Fatty Acids (FFA) Are Associated with Insulin Resistance But Do Not Explain the Relationship between Adiposity and Insulin Resistance in Hispanic Americans: The IRAS Family Study. J Clin Endocrinol Metab. 2012;97:3285-3291.Miller MR, Pereira RI, Langefeld CD et al. Levels of Free Fatty Acids (FFA) Are Associated with Insulin Resistance But Do Not Explain the Relationship between Adiposity and Insulin Resistance in Hispanic Americans: The IRAS Family Study. J Clin Endocrinol Metab. 2012;97:3285-3291.Hawkins M, Tonelli J, Kishore P, Stein D, Ragucci E, Gitig A, and Reddy K. Contribution of Elevated Free Fatty Acid Levels to the Lack of Glucose Effectiveness in Type 2 Diabetes. Diabetes. 2003;52:2748-58.Hawkins M, Tonelli J, Kishore P, Stein D, Ragucci E, Gitig A, and Reddy K. Contribution of Elevated Free Fatty Acid Levels to the Lack of Glucose Effectiveness in Type 2 Diabetes. Diabetes. 2003;52:2748-58.Santomauro ATMG, Boden G, Silva M, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48:1836-1841.Santomauro ATMG, Boden G, Silva M, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48:1836-1841.Cusi K, Kashyap S, Gastaldelli A, et al. Effect on insulin secretion and insulin action of a 48th reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Metab. 2007;292:E1775-E1781.Cusi K, Kashyap S, Gastaldelli A, et al. Effect on insulin secretion and insulin action of a 48th reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Metab. 2007;292:E1775-E1781.

The authors declare that there are no conflicts of interest present.